Research studies, summarized and reviewed by Dr. Benjamin Caplan, MD¹ (Page 11)

This large-scale genetic meta-analysis provides robust evidence that the endocannabinoid system—particularly diacylglycerol lipase alpha (DAGLA)—serves as a shared biological pathway across major psychiatric conditions including MDD, bipolar disorder, ADHD, and schizophrenia. These findings highlight the endocannabinoid signaling apparatus as a promising cross-diagnostic biomarker target for future psychiatric pharmacotherapy and integrative neuromodulation.

Clinicians should be aware of the potential relationship between video gaming and cannabis use among adolescents and young adults, but further research is needed to clarify this association.

While cannabinoids may offer targeted relief for specific PTSD symptoms like nightmares and sleep disturbances (Cluster B and E), current evidence does not support major global improvements in overall PTSD severity. Furthermore, frequent use or concurrent Cannabis Use Disorder (CUD) is strongly linked to worsening symptom trajectories, increased suicidality, and aggressive behaviors, necessitating careful screening and caution in clinical practice.

The CB1 receptor as a convergence hub linking stress, sleep and appetite regulation: An integrative neurobiological model

While observational studies and one RCT suggest modest behavioral and social communication benefits from full-spectrum, high-CBD-to-THC cannabis extracts in pediatric autism spectrum disorder, current robust trial data do not support generalized routine use. Cannabinoids should be reserved as an adjunctive therapeutic option under strict specialist medical supervision, carefully weighing the modest potential benefits against the neurodevelopmental and cognitive risks of pediatric THC exposure.

Current clinical evidence regarding the use of cannabinoids for postoperative pain in orthopedic surgery remains inconclusive due to significant trial heterogeneity and lack of product standardization. While THC/CBD combinations demonstrate modest potential for opioid-sparing effects and CBD shows early short-term promise, clinicians should exercise caution, carefully screen for concurrent substance use, and await standardized prospective trials before implementing routine perioperative cannabinoid protocols.

Clinicians should be aware of the complex relationship between cannabis use and alcohol consumption, as THC may have varying effects on alcohol craving and consumption.

Clinicians should be cautious when recommending low-dose CBD products, as the evidence for their effects is still inconclusive.

In this prospective, triple-blind, placebo-controlled trial, oral dronabinol (2.5 mg twice daily) failed to reduce opioid consumption or improve secondary pain and sleep outcomes following primary total knee arthroplasty. These findings suggest that standard low-dose synthetic THC offers no significant adjunctive benefit for acute postoperative pain management in cannabis-naïve surgical patients.

A double-blind trial testing whether a CBD-rich extract taken before a root canal reduced anxiety during the procedure or pain afterwards.